Companies › AAVantgarde Bio Srl
2 active drug programs in 2 registered trials: 2 Phase 1; Other, Ophthalmology; next expected readout Jul 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AAVB-081 AAV gene therapy delivering MYO7A cDNA | MYO7A | Phase 1 | Usher Syndrome, Type 1B | Jul 2029 |
| AAVB-039 adeno-associated virus (AAV) gene therapy delivering ABCA4 | ABCA4 | Phase 1 | Stargardt Disease | Jul 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06591793 | AAVB-081 | Phase 1 | Usher Syndrome, Type 1B | Other | Jul 2029 |
| NCT07161544 | AAVB-039 | Phase 1 | Stargardt Disease | Ophthalmology | Jul 2032 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.